Alkermes plc (ALKS)
USD 26.88
(1.09%)
USD 26.88
(1.09%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 996.24 Million USD | -7.28% |
| 2022 | 1.03 Billion USD | 72.91% |
| 2021 | 599.12 Million USD | 3.6% |
| 2020 | 578.27 Million USD | -9.62% |
| 2019 | 639.8 Million USD | 8.15% |
| 2018 | 591.57 Million USD | 22.32% |
| 2017 | 483.63 Million USD | 11.16% |
| 2016 | 435.08 Million USD | 17.83% |
| 2015 | 369.24 Million USD | 43.09% |
| 2014 | 258.05 Million USD | 53.96% |
| 2013 | 167.61 Million USD | -52.2% |
| 2012 | 350.68 Million USD | 94.73% |
| 2011 | 180.08 Million USD | 4.78% |
| 2010 | 171.87 Million USD | 15.75% |
| 2009 | 148.48 Million USD | -24.4% |
| 2008 | 196.4 Million USD | 6.91% |
| 2007 | 183.71 Million USD | 41.92% |
| 2006 | 129.45 Million USD | 7.98% |
| 2005 | 119.88 Million USD | 2.36% |
| 2004 | 117.12 Million USD | 4.5% |
| 2003 | 112.08 Million USD | -3.77% |
| 2002 | 116.47 Million USD | 35.54% |
| 2001 | 85.93 Million USD | -13.07% |
| 2000 | 98.85 Million USD | 24.73% |
| 1999 | 79.25 Million USD | 100.78% |
| 1998 | 39.47 Million USD | 5.99% |
| 1997 | 37.24 Million USD | 22.92% |
| 1996 | 30.3 Million USD | 15.21% |
| 1995 | 26.3 Million USD | -9.93% |
| 1994 | 29.2 Million USD | -20.22% |
| 1993 | 36.6 Million USD | 1009.09% |
| 1992 | 3.3 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 245.96 Million USD | 0.92% |
| 2024 Q3 | 210.28 Million USD | -7.1% |
| 2024 Q2 | 226.36 Million USD | -7.97% |
| 2023 Q4 | 243.72 Million USD | -11.56% |
| 2023 Q1 | 276.91 Million USD | 2.07% |
| 2023 Q2 | 214.15 Million USD | -22.66% |
| 2023 FY | 960.55 Million USD | -7.28% |
| 2023 Q3 | 275.58 Million USD | 28.68% |
| 2022 FY | 1.03 Billion USD | 72.91% |
| 2022 Q1 | 154.01 Million USD | -9.41% |
| 2022 Q2 | 252.31 Million USD | 63.82% |
| 2022 Q3 | 161.94 Million USD | -35.82% |
| 2022 Q4 | 271.29 Million USD | 67.52% |
| 2021 Q1 | 134.57 Million USD | -13.57% |
| 2021 FY | 599.12 Million USD | 3.6% |
| 2021 Q2 | 148.69 Million USD | 10.5% |
| 2021 Q3 | 145.82 Million USD | -1.93% |
| 2021 Q4 | 170.02 Million USD | 16.59% |
| 2020 Q1 | 143.1 Million USD | -13.07% |
| 2020 Q2 | 141.91 Million USD | -0.83% |
| 2020 Q3 | 137.57 Million USD | -3.06% |
| 2020 Q4 | 155.69 Million USD | 13.18% |
| 2020 FY | 578.27 Million USD | -9.62% |
| 2019 Q3 | 158.87 Million USD | -3.79% |
| 2019 Q2 | 165.13 Million USD | 9.24% |
| 2019 FY | 639.8 Million USD | 8.15% |
| 2019 Q1 | 151.17 Million USD | -4.11% |
| 2019 Q4 | 164.62 Million USD | 3.62% |
| 2018 Q3 | 145.2 Million USD | -6.02% |
| 2018 Q1 | 134.21 Million USD | 6.07% |
| 2018 FY | 591.57 Million USD | 22.32% |
| 2018 Q4 | 157.65 Million USD | 8.57% |
| 2018 Q2 | 154.5 Million USD | 15.12% |
| 2017 Q4 | 126.53 Million USD | 9.77% |
| 2017 FY | 483.63 Million USD | 11.16% |
| 2017 Q1 | 117.4 Million USD | 4.39% |
| 2017 Q2 | 124.42 Million USD | 5.98% |
| 2017 Q3 | 115.27 Million USD | -7.35% |
| 2016 Q4 | 112.46 Million USD | 5.64% |
| 2016 Q3 | 106.46 Million USD | -4.32% |
| 2016 FY | 435.08 Million USD | 17.83% |
| 2016 Q2 | 111.27 Million USD | 6.11% |
| 2016 Q1 | 104.87 Million USD | 3.14% |
| 2015 Q1 | 78.27 Million USD | 11.74% |
| 2015 FY | 369.24 Million USD | 43.09% |
| 2015 Q4 | 101.67 Million USD | -1.95% |
| 2015 Q3 | 103.7 Million USD | 21.16% |
| 2015 Q2 | 85.59 Million USD | 9.35% |
| 2014 FY | 258.05 Million USD | 53.96% |
| 2014 Q1 | 55.12 Million USD | -50.31% |
| 2014 Q2 | 65.75 Million USD | 19.28% |
| 2014 Q4 | 70.04 Million USD | 4.34% |
| 2014 Q3 | 67.13 Million USD | 2.1% |
| 2013 Q3 | 52.31 Million USD | 14.59% |
| 2013 Q1 | 45 Million USD | 11.34% |
| 2013 FY | 167.61 Million USD | -52.2% |
| 2013 Q4 | 110.93 Million USD | 112.07% |
| 2013 Q2 | 45.64 Million USD | 1.44% |
| 2012 FY | 350.68 Million USD | 94.73% |
| 2012 Q4 | 40.41 Million USD | -47.55% |
| 2012 Q3 | 77.06 Million USD | -1.23% |
| 2012 Q2 | 78.02 Million USD | -43.07% |
| 2012 Q1 | 137.06 Million USD | 56.01% |
| 2011 Q3 | 66.21 Million USD | 11.19% |
| 2011 Q4 | 87.85 Million USD | 32.69% |
| 2011 FY | 180.08 Million USD | 4.78% |
| 2011 Q2 | 59.54 Million USD | 14.53% |
| 2011 Q1 | 51.99 Million USD | 20.84% |
| 2010 FY | 171.87 Million USD | 15.75% |
| 2010 Q1 | 45.41 Million USD | 12.66% |
| 2010 Q4 | 43.02 Million USD | 1.55% |
| 2010 Q3 | 42.36 Million USD | -0.78% |
| 2010 Q2 | 42.7 Million USD | -5.98% |
| 2009 Q2 | 44.85 Million USD | -1.79% |
| 2009 Q1 | 45.67 Million USD | 22.65% |
| 2009 FY | 148.48 Million USD | -24.4% |
| 2009 Q4 | 40.31 Million USD | -2.36% |
| 2009 Q3 | 41.28 Million USD | -7.95% |
| 2008 Q1 | 59.93 Million USD | 31.32% |
| 2008 Q3 | 31.38 Million USD | -8.18% |
| 2008 Q4 | 37.23 Million USD | 18.63% |
| 2008 FY | 196.4 Million USD | 6.91% |
| 2008 Q2 | 34.18 Million USD | -42.96% |
| 2007 Q4 | 45.64 Million USD | 6.63% |
| 2007 Q2 | 48.01 Million USD | -3.1% |
| 2007 Q1 | 49.55 Million USD | 7.09% |
| 2007 FY | 183.71 Million USD | 41.92% |
| 2007 Q3 | 42.8 Million USD | -10.86% |
| 2006 Q4 | 46.27 Million USD | 1.71% |
| 2006 Q3 | 45.49 Million USD | 7.31% |
| 2006 Q2 | 42.39 Million USD | 9.93% |
| 2006 Q1 | 38.56 Million USD | 21.15% |
| 2006 FY | 129.45 Million USD | 7.98% |
| 2005 FY | 119.88 Million USD | 2.36% |
| 2005 Q4 | 31.83 Million USD | 11.78% |
| 2005 Q1 | 31.82 Million USD | 18.18% |
| 2005 Q2 | 30.57 Million USD | -3.92% |
| 2005 Q3 | 28.47 Million USD | -6.85% |
| 2004 Q4 | 26.92 Million USD | -10.15% |
| 2004 Q1 | 36.67 Million USD | 32.48% |
| 2004 FY | 117.12 Million USD | 4.5% |
| 2004 Q2 | 31.17 Million USD | -15.02% |
| 2004 Q3 | 29.96 Million USD | -3.86% |
| 2003 Q1 | 17.55 Million USD | -33.85% |
| 2003 Q3 | 29.32 Million USD | 6.81% |
| 2003 Q4 | 27.68 Million USD | -5.58% |
| 2003 FY | 112.08 Million USD | -3.77% |
| 2003 Q2 | 27.45 Million USD | 56.42% |
| 2002 FY | 116.47 Million USD | 35.54% |
| 2002 Q4 | 26.53 Million USD | -29.02% |
| 2002 Q1 | 32.44 Million USD | 12.19% |
| 2002 Q2 | 30.61 Million USD | -5.65% |
| 2002 Q3 | 37.38 Million USD | 22.11% |
| 2001 FY | 85.93 Million USD | -13.07% |
| 2001 Q3 | 29 Million USD | 11.19% |
| 2001 Q1 | 24.19 Million USD | 19.83% |
| 2001 Q2 | 26.08 Million USD | 7.82% |
| 2001 Q4 | 28.92 Million USD | -0.28% |
| 2000 Q2 | 22.4 Million USD | -38.71% |
| 2000 FY | 98.85 Million USD | 24.73% |
| 2000 Q4 | 20.18 Million USD | 5.41% |
| 2000 Q1 | 36.56 Million USD | 40.76% |
| 2000 Q3 | 19.15 Million USD | -14.52% |
| 1999 FY | 79.25 Million USD | 100.78% |
| 1999 Q3 | 20.55 Million USD | 30.33% |
| 1999 Q2 | 15.76 Million USD | -58.65% |
| 1999 Q1 | 38.13 Million USD | 152.68% |
| 1999 Q4 | 25.97 Million USD | 26.39% |
| 1998 Q1 | 10.54 Million USD | 1.23% |
| 1998 FY | 39.47 Million USD | 5.99% |
| 1998 Q4 | 15.09 Million USD | 5.18% |
| 1998 Q3 | 14.34 Million USD | 22.87% |
| 1998 Q2 | 11.67 Million USD | 10.69% |
| 1997 Q1 | 10.27 Million USD | 10.01% |
| 1997 FY | 37.24 Million USD | 22.92% |
| 1997 Q4 | 10.42 Million USD | 16.05% |
| 1997 Q3 | 8.98 Million USD | -5.69% |
| 1997 Q2 | 9.52 Million USD | -7.34% |
| 1996 Q3 | 8.56 Million USD | -5.38% |
| 1996 Q4 | 9.34 Million USD | 9.02% |
| 1996 Q2 | 9.05 Million USD | -11.21% |
| 1996 Q1 | 10.2 Million USD | 52.24% |
| 1996 FY | 30.3 Million USD | 15.21% |
| 1995 Q2 | 6.7 Million USD | 6.35% |
| 1995 Q1 | 6.3 Million USD | 0.0% |
| 1995 Q4 | 6.7 Million USD | 0.0% |
| 1995 FY | 26.3 Million USD | -9.93% |
| 1995 Q3 | 6.7 Million USD | 0.0% |
| 1994 FY | 29.2 Million USD | -20.22% |
| 1994 Q4 | 6.3 Million USD | -8.7% |
| 1994 Q3 | 6.9 Million USD | 1.47% |
| 1994 Q2 | 6.8 Million USD | -70.94% |
| 1994 Q1 | 23.4 Million USD | 836.0% |
| 1993 Q4 | 2.5 Million USD | 47.06% |
| 1993 Q1 | 23 Million USD | 310.71% |
| 1993 FY | 36.6 Million USD | 1009.09% |
| 1993 Q2 | 1.5 Million USD | -93.48% |
| 1993 Q3 | 1.7 Million USD | 13.33% |
| 1992 Q3 | 1 Million USD | 25.0% |
| 1992 FY | 3.3 Million USD | 0.0% |
| 1992 Q2 | 800 Thousand USD | 108.25% |
| 1992 Q1 | -9.7 Million USD | 0.0% |
| 1992 Q4 | 5.6 Million USD | 460.0% |
| 1991 Q4 | - USD | -100.0% |
| 1991 Q2 | 1.1 Million USD | 0.0% |
| 1991 Q3 | 500 Thousand USD | -54.55% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Caribou Biosciences, Inc. | 150.53 Million USD | -561.799% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -14698.786% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -3280.658% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -1865.254% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -493.615% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -523.484% |
| Agenus Inc. | 78.18 Million USD | -1174.249% |
| Fortress Biotech, Inc. | 200.19 Million USD | -397.638% |
| GlycoMimetics, Inc. | 39.28 Million USD | -2435.926% |
| Novavax, Inc. | 779.12 Million USD | -27.867% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -488.53% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -4376.906% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -930.138% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -653.733% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -395.361% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 44.655% |
| AlloVir, Inc. | 180.93 Million USD | -450.616% |
| Aptorum Group Limited | 10.56 Thousand USD | -9428690.46% |
| Ardelyx, Inc. | 169.93 Million USD | -486.244% |
| Bicycle Therapeutics plc | 216.92 Million USD | -359.265% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -479.543% |
| Chimerix, Inc. | 93.38 Million USD | -966.77% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -7062.27% |
| CRISPR Therapeutics AG | 463.49 Million USD | -114.943% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -2945.227% |
| Precision BioSciences, Inc. | 92.46 Million USD | -977.454% |
| Dyadic International, Inc. | 9.15 Million USD | -10784.727% |
| Elevation Oncology, Inc. | 45.44 Million USD | -2092.202% |
| Fortress Biotech, Inc. | 200.19 Million USD | -397.638% |
| GT Biopharma, Inc. | 13.57 Million USD | -7238.288% |
| Immix Biopharma, Inc. | 16.14 Million USD | -6072.102% |
| Innoviva, Inc. | 132.15 Million USD | -653.852% |
| IO Biotech, Inc. | 91.44 Million USD | -989.472% |
| Jaguar Health, Inc. | 42.01 Million USD | -2271.167% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -1081.464% |
| ContextLogic Inc. | 387 Million USD | -157.428% |
| AbCellera Biologics Inc. | 275.23 Million USD | -261.966% |
| Lantern Pharma Inc. | 17.87 Million USD | -5472.603% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -11688.498% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -123.505% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -161.828% |
| MEI Pharma, Inc. | 34.78 Million USD | -2764.01% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -1075.983% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -3998.663% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -520.559% |
| NextCure, Inc. | 67.63 Million USD | -1372.93% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -2942.344% |
| ChromaDex Corporation | 56.37 Million USD | -1667.052% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -531.279% |
| Incyte Corporation | 1.19 Billion USD | 16.317% |
| Opthea Limited | 191.96 Million USD | -418.966% |
| MiMedx Group, Inc. | 229.72 Million USD | -333.665% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -1775.238% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -965.755% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -36106.259% |
| Vaxcyte, Inc. | 468.04 Million USD | -112.854% |
| PDS Biotechnology Corporation | 43.04 Million USD | -2214.417% |
| Pharming Group N.V. | 225.49 Million USD | -341.812% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -1272.883% |
| Onconetix, Inc. | 34.9 Million USD | -2753.965% |
| Acelyrin, Inc. | 422.06 Million USD | -136.041% |
| PureTech Health plc | 144.59 Million USD | -588.981% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -1112.037% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -306.369% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -5030.392% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -3998.663% |
| ESSA Pharma Inc. | 32.13 Million USD | -3000.276% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -664.796% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -3265.014% |
| Seer, Inc. | 110.49 Million USD | -801.662% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -335.651% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -2530.769% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -3128.381% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -7726330.898% |
| Summit Therapeutics Inc. | 87.68 Million USD | -1036.152% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -2587.907% |
| Senti Biosciences, Inc. | 94.7 Million USD | -951.947% |
| ImmuCell Corporation | 9.61 Million USD | -10258.828% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -3137.613% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -1128.993% |
| Precigen, Inc. | 84.18 Million USD | -1083.457% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -1655.221% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -7716.146% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -706.331% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -491.469% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -25172.295% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -146.863% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -1311.233% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -2822.828% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -3256.398% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -5606.857% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -449.498% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -292.155% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -5163.067% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -353.189% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -284.021% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -1742.171% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -9924.971% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -283.675% |
| Aptose Biosciences Inc. | 52.35 Million USD | -1802.831% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -6813.394% |
| Soligenix, Inc. | 7.79 Million USD | -12680.166% |
| Century Therapeutics, Inc. | 56.07 Million USD | -1676.758% |
| Kura Oncology, Inc. | 165.8 Million USD | -500.858% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -770.031% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -11875.55% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -40044.679% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -825.037% |
| Autolus Therapeutics plc | 196.72 Million USD | -406.413% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -1076.803% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -755.492% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -5039.793% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -209.626% |
| GRI Bio, Inc. | 11.33 Million USD | -8692.992% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -14019.731% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -659.374% |
| IGM Biosciences, Inc. | 265.59 Million USD | -275.105% |
| INmune Bio, Inc. | 29.89 Million USD | -3232.372% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -477.353% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -2371.197% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -6134.58% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -6228.766% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -1504.313% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -826.551% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -261.361% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -230.484% |
| Verastem, Inc. | 92.08 Million USD | -981.888% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -5453.52% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -436.409% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -720.584% |
| Histogen Inc. | 14.27 Million USD | -6880.423% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -6107.859% |
| Surrozen, Inc. | 18.55 Million USD | -5270.598% |
| Organovo Holdings, Inc. | 14.91 Million USD | -6579.49% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -19471.706% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -1569.504% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -3784.454% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -2019.402% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -12952.096% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -459.261% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -1956.322% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -306.624% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -6383.202% |
| Apollomics, Inc. | 54.14 Million USD | -1740.129% |
| Amarin Corporation plc | 272.35 Million USD | -265.787% |
| Mesoblast Limited | 5.9 Million USD | -16779.803% |
| Turnstone Biologics Corp. | 78.33 Million USD | -1171.728% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -308.093% |
| Synaptogenix, Inc. | 8.31 Million USD | -11882.962% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -6730.152% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -293.686% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -2889.03% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -11180.936% |
| Exelixis, Inc. | 1.58 Billion USD | 37.216% |
| Better Therapeutics, Inc. | 38.26 Million USD | -2503.748% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -329.324% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | -16.492% |
| NLS Pharmaceutics AG | 11.8 Million USD | -8337.712% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -12288.183% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -3221.595% |
| Gritstone bio, Inc. | 148.37 Million USD | -571.442% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1346.749% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -5989.442% |
| Avid Bioservices, Inc. | 25.99 Million USD | -3732.305% |
| Insmed Incorporated | 949.26 Million USD | -4.95% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -6249.646% |
| MediWound Ltd. | 18.86 Million USD | -5180.083% |
| OmniAb, Inc. | 83.89 Million USD | -1087.492% |
| Alector, Inc. | 248.8 Million USD | -300.417% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -325.187% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -1806.654% |
| Zai Lab Limited | 547.47 Million USD | -81.971% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -149.902% |
| Aura Biosciences, Inc. | 84.99 Million USD | -1072.178% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -303.113% |
| Immunic, Inc. | 99.22 Million USD | -904.047% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -526.523% |
| Veracyte, Inc. | 357.93 Million USD | -178.333% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 88.95% |
| FibroGen, Inc. | 398.11 Million USD | -150.242% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -6910.88% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -14363.613% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -13880.964% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 69.399% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -3750.524% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -214.727% |
| TG Therapeutics, Inc. | 198.47 Million USD | -401.95% |
| Galecto, Inc. | 35.62 Million USD | -2696.323% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -2348.441% |
| Fortrea Holdings Inc. | 457.3 Million USD | -117.854% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -1735.451% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -3349.844% |
| XBiotech Inc. | 37.51 Million USD | -2555.948% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1346.749% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -4724.669% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -601.28% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -905.547% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -799.821% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | -3.965% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -3353.791% |
| Vaxxinity, Inc. | 56.05 Million USD | -1677.392% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -131.341% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -4365.806% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -798.596% |
| NexImmune, Inc. | 28.16 Million USD | -3436.862% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -17912.211% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -5467.95% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 64.613% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -3813.139% |
| Scopus BioPharma Inc. | 11.71 Million USD | -8404.11% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -684.063% |
| Ainos, Inc. | 12.95 Million USD | -7591.438% |
| Pluri Inc. | 22.48 Million USD | -4331.699% |
| Prothena Corporation plc | 282.4 Million USD | -252.771% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -398.068% |
| Celularity Inc. | 215.05 Million USD | -363.245% |
| Rallybio Corporation | 78.93 Million USD | -1162.157% |
| Cue Biopharma, Inc. | 19.54 Million USD | -4997.974% |
| MeiraGTx Holdings plc | 151.07 Million USD | -559.425% |
| Omeros Corporation | 94.75 Million USD | -951.436% |
| Humacyte, Inc. | 23.49 Million USD | -4139.886% |
| Immunocore Holdings plc | 308.04 Million USD | -223.414% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -29287.788% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -1046.89% |
| Blueprint Medicines Corporation | 722.86 Million USD | -37.82% |
| CalciMedica, Inc. | 21.81 Million USD | -4466.375% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -1234.377% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -481.597% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -237.779% |
| Pulmatrix, Inc. | 22.03 Million USD | -4420.583% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -2781.406% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -1021.065% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -80.621% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -1273.166% |
| Cytokinetics, Incorporated | 173.61 Million USD | -473.835% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -2794.465% |
| Nutriband Inc. | 5.73 Million USD | -17274.27% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -2184.287% |
| Vor Biopharma Inc. | 126.03 Million USD | -690.446% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 16.224% |
| Evogene Ltd. | 27.79 Million USD | -3484.908% |
| ProKidney Corp. | 151.52 Million USD | -557.493% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -1243.102% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -12851.309% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | -62.195% |
| CorMedix Inc. | 48.95 Million USD | -1934.908% |
| BioLineRx Ltd. | 50.8 Million USD | -1861.037% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -561.079% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -2516.742% |
| Atai Life Sciences N.V. | 125.78 Million USD | -692.023% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -1120.302% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -1123.754% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -294.472% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -2942.902% |
| MediciNova, Inc. | 10.9 Million USD | -9039.649% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -673.363% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -13623.296% |
| GeoVax Labs, Inc. | 6.02 Million USD | -16442.965% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -109.137% |
| Biomea Fusion, Inc. | 126.13 Million USD | -689.825% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 24.057% |
| Mereo BioPharma Group plc | 35.84 Million USD | -2679.549% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -421.352% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -333.237% |
| Absci Corporation | 73.66 Million USD | -1252.382% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -3511.943% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -645.749% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -311.397% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -280.177% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -378.978% |
| Allakos Inc. | 196.05 Million USD | -408.144% |
| Imunon, Inc. | 20.31 Million USD | -4805.097% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -777.99% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -170.27% |
| BioAtla, Inc. | 129.68 Million USD | -668.193% |
| NLS Pharmaceutics AG | 11.8 Million USD | -8337.712% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -6188.241% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -1073.186% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -2285.761% |
| XOMA Corporation | 46.46 Million USD | -2044.171% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -796.138% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -599.302% |
| aTyr Pharma, Inc. | 12.97 Million USD | -7575.83% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -861.108% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -476.298% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -291.047% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -2563.19% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -12012.687% |
| Akari Therapeutics, Plc | 16.8 Million USD | -5827.919% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -43710.868% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -232.839% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -14705.855% |
| UroGen Pharma Ltd. | 138.88 Million USD | -617.302% |
| Sutro Biopharma, Inc. | 243 Million USD | -309.963% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -13594.815% |
| Orgenesis Inc. | 45.75 Million USD | -2077.254% |
| Entera Bio Ltd. | 8.86 Million USD | -11144.312% |
| GH Research PLC | 41.22 Million USD | -2316.782% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -3775.237% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -1099.53% |
| Xencor, Inc. | 306.97 Million USD | -224.534% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -20093.06% |
| Replimune Group, Inc. | 234.77 Million USD | -324.344% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -4762.135% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -419.43% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -14705.855% |
| Portage Biotech Inc. | 18.19 Million USD | -5374.18% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -13623.296% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -849.158% |
| OncoCyte Corporation | 25.63 Million USD | -3785.969% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -16243.672% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -8595.476% |
| Purple Biotech Ltd. | -22.46 Million USD | 4534.264% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -5945.182% |
| scPharmaceuticals Inc. | 65.17 Million USD | -1428.5% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -11686.077% |
| HilleVax, Inc. | 133.34 Million USD | -647.119% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -9586.398% |
| Tharimmune, Inc. | 9.45 Million USD | -10436.466% |
| Genprex, Inc. | 31.06 Million USD | -3107.43% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -431.258% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -3075.084% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -130128.235% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -18190.083% |
| OKYO Pharma Limited | 8243.57 USD | -12085028.167% |
| Savara Inc. | 15.74 Million USD | -6227.38% |
| Curis, Inc. | 58.35 Million USD | -1607.216% |
| Daré Bioscience, Inc. | 33.6 Million USD | -2864.188% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -19463.051% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -13252.714% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -3586.796% |
| BeiGene, Ltd. | 3.28 Billion USD | 69.688% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -4896.394% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | -99.743% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -548.378% |
| Erasca, Inc. | 141.52 Million USD | -603.936% |
| bluebird bio, Inc. | 240.23 Million USD | -314.702% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -21906.886% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 42.95% |
| DBV Technologies S.A. | 92.16 Million USD | -980.996% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -21906.886% |
| Moderna, Inc. | 6.39 Billion USD | 84.419% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -2238.112% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -6834.749% |
| Molecular Templates, Inc. | 63.09 Million USD | -1479.062% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -1393.6% |
| Travere Therapeutics, Inc. | 472 Million USD | -111.068% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -595.164% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -1504.726% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -2194.757% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -378.665% |
| MacroGenics, Inc. | 217.21 Million USD | -358.645% |
| RenovoRx, Inc. | 11.39 Million USD | -8642.067% |
| Adicet Bio, Inc. | 152.03 Million USD | -555.261% |
| Prime Medicine, Inc. | 186.63 Million USD | -433.782% |
| Aditxt, Inc. | 25.95 Million USD | -3738.985% |
| Adagene Inc. | 41.83 Million USD | -2281.577% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -13528.354% |
| Quantum-Si incorporated | 111.65 Million USD | -792.222% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -479.718% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -6734.009% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -2681.101% |
| SciSparc Ltd. | 9.01 Million USD | -10955.887% |
| Vericel Corporation | 142.04 Million USD | -601.384% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -11408.429% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -4214.884% |
| Generation Bio Co. | 144.46 Million USD | -589.601% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -1099.863% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -1052.262% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -236.888% |
| Invivyd, Inc. | 205.75 Million USD | -384.19% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -1280.626% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -10522.654% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -1223.845% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -9584.514% |
| 2seventy bio, Inc. | 289.88 Million USD | -243.667% |
| ADMA Biologics, Inc. | 66.58 Million USD | -1396.179% |
| Clene Inc. | 41.07 Million USD | -2325.55% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -7678.38% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -1718.1% |
| GeoVax Labs, Inc. | 6.02 Million USD | -16442.965% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -182.986% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -2612.201% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -2853.765% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -860.682% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -2957.001% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -485.07% |
| Vir Biotechnology, Inc. | 767.72 Million USD | -29.767% |
| Evaxion Biotech A/S | 22.27 Million USD | -4373.489% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -634.998% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -324.147% |
| Trevena, Inc. | 38.41 Million USD | -2493.513% |
| Surrozen, Inc. | 18.55 Million USD | -5270.598% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -1146.164% |
| Cingulate Inc. | 22.75 Million USD | -4277.335% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 13397.464% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -2130.385% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -11999.261% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -871.398% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | -32.113% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -1504.933% |
| Clearmind Medicine Inc. | 8.74 Million USD | -11296.935% |
| Kronos Bio, Inc. | 128.11 Million USD | -677.6% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -1084.991% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -33866.965% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -888.075% |
| Statera Biopharma, Inc. | 28.82 Million USD | -3355.647% |
| ImmunityBio, Inc. | 362.87 Million USD | -174.545% |
| Korro Bio, Inc. | 84.53 Million USD | -1078.515% |
| Kineta, Inc. | 21.15 Million USD | -4609.047% |
| BioVie Inc. | 31.95 Million USD | -3018.121% |
| Codexis, Inc. | 66.51 Million USD | -1397.709% |
| Celularity Inc. | 215.05 Million USD | -363.245% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -339.609% |
| Celcuity Inc. | 66.23 Million USD | -1404.214% |
| Virax Biolabs Group Limited | 6.54 Million USD | -15116.686% |
| Cibus, Inc. | 320.3 Million USD | -211.03% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -2216.851% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -2843.641% |
| IN8bio, Inc. | 30.33 Million USD | -3183.931% |
| Kodiak Sciences Inc. | 277.32 Million USD | -259.239% |
| Annexon, Inc. | 143.72 Million USD | -593.171% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -680.812% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -4248.71% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -155563.438% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -27.792% |
| Eyenovia, Inc. | 25.4 Million USD | -3821.233% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -610.007% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -17811.65% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -1158.951% |
| Arcellx, Inc. | 200.19 Million USD | -397.628% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -2070.471% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -360.349% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -9905.484% |
| Moolec Science SA | 52.75 Million USD | -1788.596% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -1529.504% |
| Geron Corporation | 70.44 Million USD | -1314.298% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -2040.623% |
| Royalty Pharma plc | 862.4 Million USD | -15.52% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -959.025% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -10580.321% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -4302.61% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -379.398% |
| Humacyte, Inc. | 23.49 Million USD | -4139.886% |
| Structure Therapeutics Inc. | 102.77 Million USD | -869.347% |
| 89bio, Inc. | 151.2 Million USD | -558.875% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -1143.256% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -6751.761% |
| Genelux Corporation | 24.33 Million USD | -3993.881% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -2836.786% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -476.301% |
| Notable Labs, Ltd. | 14.77 Million USD | -6645.064% |
| Liquidia Corporation | 87.98 Million USD | -1032.304% |
| Mustang Bio, Inc. | 48.5 Million USD | -1954.073% |
| Immunovant, Inc. | 282.7 Million USD | -252.393% |
| Quantum-Si incorporated | 111.65 Million USD | -792.222% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -4319.118% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -4584.469% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -876.597% |
| Acasti Pharma Inc. | 11.3 Million USD | -8715.556% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -4246.413% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -6134.58% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -2040.531% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -87707.471% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -6171.22% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -3316.833% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -2307.322% |
| PepGen Inc. | 84.76 Million USD | -1075.29% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -3262.175% |
| United Therapeutics Corporation | 885.1 Million USD | -12.557% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -4250.989% |
| Solid Biosciences Inc. | 104.31 Million USD | -855.036% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -2944.247% |
| Immuneering Corporation | 58.41 Million USD | -1605.524% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -19471.706% |
| Silo Pharma, Inc. | 3.92 Million USD | -25302.412% |
| Belite Bio, Inc | 31.66 Million USD | -3045.908% |
| XOMA Corporation | 46.46 Million USD | -2044.171% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -1374.828% |
| Bionomics Limited | 17.89 Billion USD | 94.432% |
| Apogee Therapeutics, Inc. | 93 Million USD | -971.198% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 2892.169% |
| uniQure N.V. | 285.08 Million USD | -249.455% |
| Cassava Sciences, Inc. | 105.95 Million USD | -840.236% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -13528.354% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -412.982% |
| Forte Biosciences, Inc. | 32.47 Million USD | -2967.543% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -11890.316% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -3289.168% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -17811.65% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -6910.88% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -11107.627% |
| Altimmune, Inc. | 30.55 Million USD | -3160.394% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -132.958% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 2892.169% |
| Compugen Ltd. | 43.97 Million USD | -2165.689% |
| Peak Bio, Inc. | 1249.13 USD | -79755089.612% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -1244.099% |
| Benitec Biopharma Inc. | 22.38 Million USD | -4351.104% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -309.659% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -3390.334% |
| Zura Bio Limited | 62.63 Million USD | -1490.482% |
| PolyPid Ltd. | 21.04 Million USD | -4633.885% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -6020.951% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -3390.334% |
| Instil Bio, Inc. | 85.78 Million USD | -1061.329% |
| argenx SE | 1.53 Billion USD | 35.036% |
| Immunome, Inc. | 122.82 Million USD | -711.143% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -1955.26% |
| Verona Pharma plc | 67.15 Million USD | -1383.585% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -3748.739% |
| Shattuck Labs, Inc. | 93.61 Million USD | -964.206% |
| CervoMed Inc. | 14.95 Million USD | -6560.393% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -1309.058% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -11560.183% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -1853.424% |
| Moolec Science SA | 52.75 Million USD | -1788.596% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -5956.781% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -651.571% |
| AnaptysBio, Inc. | 181.56 Million USD | -448.69% |
| Design Therapeutics, Inc. | 78.19 Million USD | -1174.135% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -1044.571% |
| NeurAxis, Inc. | 8.82 Million USD | -11193.771% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -7816.138% |
| Lumos Pharma, Inc. | 38.66 Million USD | -2476.609% |
| Achilles Therapeutics plc | 75.25 Million USD | -1223.827% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -3748.739% |
| 180 Life Sciences Corp. | 13.47 Million USD | -7291.92% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -3659.072% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -33866.965% |
| Nutriband Inc. | 5.73 Million USD | -17274.27% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -799.301% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -1690.103% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -1858.069% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -1407.203% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -1740.704% |
| Palisade Bio, Inc. | 13.32 Million USD | -7379.324% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -2093.94% |
| Beam Therapeutics Inc. | 554.19 Million USD | -79.765% |
| Neurogene Inc. | 55.58 Million USD | -1692.357% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -300.922% |
| AEON Biopharma, Inc. | 48.42 Million USD | -1957.127% |
| Sesen Bio, Inc. | 78.38 Million USD | -1171.03% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -1092.695% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -7814.946% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -120.901% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -1033.515% |
| Athira Pharma, Inc. | 125.46 Million USD | -694.037% |
| Vaccinex, Inc. | 23.45 Million USD | -4147.478% |
| HCW Biologics Inc. | 21.02 Million USD | -4637.82% |
| XOMA Corporation | 46.46 Million USD | -2044.171% |
| Nektar Therapeutics | 190.9 Million USD | -421.86% |
| Arvinas, Inc. | 480 Million USD | -107.551% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -43710.868% |
| Merus N.V. | 200.49 Million USD | -396.896% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -863.907% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -2777.66% |
| Rezolute, Inc. | 70.38 Million USD | -1315.384% |
| Clene Inc. | 41.07 Million USD | -2325.55% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -5982.655% |
| BeyondSpring Inc. | 24.86 Million USD | -3906.62% |
| Synlogic, Inc. | 58.53 Million USD | -1602.054% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -5468.109% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -22078.228% |
| Peak Bio, Inc. | 1249.13 USD | -79755089.612% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -1548.159% |
| Krystal Biotech, Inc. | 160.42 Million USD | -521.0% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -268.12% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -186.246% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -46092.345% |
| MannKind Corporation | 125.59 Million USD | -693.208% |
| Ikena Oncology, Inc. | 84.57 Million USD | -1077.916% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -10227.003% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -1011.869% |
| Gossamer Bio, Inc. | 183.75 Million USD | -442.148% |
| CohBar, Inc. | 12.38 Million USD | -7941.832% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -1864.053% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -3511.943% |
| Legend Biotech Corporation | 583.14 Million USD | -70.84% |
| Mural Oncology plc | 192.07 Million USD | -418.686% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -1383.679% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -6070.513% |
| Disc Medicine, Inc. | 91.12 Million USD | -993.274% |
| Champions Oncology, Inc. | 28.11 Million USD | -3444.098% |
| REGENXBIO Inc. | 321.15 Million USD | -210.205% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -18482.401% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -1686.796% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -2457.057% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -771.172% |
| Vaxart, Inc. | 90.72 Million USD | -998.082% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -11593.017% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -2227.999% |
| Cellectis S.A. | 97.32 Million USD | -923.681% |
| Longeveron Inc. | 21.25 Million USD | -4588.216% |
| Repare Therapeutics Inc. | 167.35 Million USD | -495.282% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 26.791% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -1217.002% |
| Revolution Medicines, Inc. | 498.76 Million USD | -99.743% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -14876.639% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -2166.565% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -1235.629% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -1330.668% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -8907.649% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 79.136% |
| Denali Therapeutics Inc. | 527.23 Million USD | -88.959% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -11408.429% |
| Veru Inc. | 101.34 Million USD | -882.994% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -4156.188% |
| Cingulate Inc. | 22.75 Million USD | -4277.335% |
| Passage Bio, Inc. | 108.38 Million USD | -819.139% |
| Context Therapeutics Inc. | 25.07 Million USD | -3873.443% |
| Exicure, Inc. | 14.07 Million USD | -6977.621% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -383.464% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -2200.746% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -10755.558% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -294.579% |
| Nuvalent, Inc. | 149.49 Million USD | -566.421% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -12249.797% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -861.164% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -4544.72% |
| OmniAb, Inc. | 83.89 Million USD | -1087.492% |
| Anew Medical, Inc. | 1.3 Million USD | -76484.763% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -2940.673% |
| Lipocine Inc. | 15.08 Million USD | -6506.345% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -1354.098% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -1208.234% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -2371.197% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -767.485% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -4350.706% |
| Sage Therapeutics, Inc. | 664.14 Million USD | -50.004% |
| Ocugen, Inc. | 71.56 Million USD | -1292.047% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -961.349% |
| Q32 Bio Inc. | 92.68 Million USD | -974.931% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -4605.044% |
| Alumis Inc. Common Stock | 158.17 Million USD | -529.842% |
| Equillium, Inc. | 50.6 Million USD | -1868.632% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -1496.395% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -7064.374% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -5180.892% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -2021.885% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -818.487% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -7938.957% |
| Dominari Holdings Inc. | 23.83 Million USD | -4079.761% |
| Edesa Biotech, Inc. | 9.22 Million USD | -10702.04% |
| vTv Therapeutics Inc. | 11.9 Million USD | -8266.893% |
| Bio-Techne Corporation | 563.03 Million USD | -76.941% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -143.697% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -270.688% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -653.151% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -6813.094% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -508.595% |
| Nkarta, Inc. | 131.65 Million USD | -656.738% |
| BioCardia, Inc. | 12.12 Million USD | -8119.173% |
| Iterum Therapeutics plc | 47.46 Million USD | -1998.774% |